Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Clin Genitourin Cancer. 2021 Jun;19(3):272.e1-272.e7. doi: 10.1016/j.clgc.2020.09.002. Epub 2020 Sep 18.
The objective of this study was to evaluate the performance of different tumor diameters for identifying ≥ pT2 upper tract urothelial carcinoma (UTUC) at radical nephroureterectomy.
This was a multi-institutional retrospective study that included 932 patients who underwent radical nephroureterectomy for nonmetastatic UTUC between 2000 and 2016. Tumor sizes were pathologically assessed and categorized into 4 groups: ≤ 1 cm, 1.1 to 2 cm, 2.1 to 3 cm, and > 3 cm. We performed logistic regression and decision-curve analyses.
Overall, 45 (4.8%) patients had a tumor size ≤ 1 cm, 141 (15.1%) between 1.1 and 2 cm, 247 (26.5%) between 2.1 and 3 cm, and 499 (53.5%) > 3 cm. In preoperative predictive models that were adjusted for the effects of standard clinicopathologic features, tumor diameters > 2 cm (odds ratio, 2.38; 95% confidence interval, 1.70-3.32; P < .001) and > 3 cm (odds ratio, 1.81; 95% confidence interval, 1.38-2.38; P < .001) were independently associated with ≥ pT2 pathologic staging. The addition of the > 2-cm diameter cutoff improved the area under the curve of the model from 58.8% to 63.0%. Decision-curve analyses demonstrated a clinical net benefit of 0.09 and a net reduction of 8 per 100 patients.
The 2-cm cutoff appears to be most useful in identifying patients at risk of harboring ≥ pT2 UTUC. This confirms the current European Association of Urology guideline's risk stratification. Tumor size alone is not sufficient for optimal risk stratification, rather a constellation of features is needed to select the best candidate for kidney-sparing surgery.
本研究旨在评估不同肿瘤直径在根治性肾输尿管切除术(radical nephroureterectomy)中识别≥pT2 上尿路上皮癌(UTUC)的表现。
这是一项多机构回顾性研究,纳入了 2000 年至 2016 年间接受根治性肾输尿管切除术治疗非转移性 UTUC 的 932 例患者。肿瘤大小通过病理评估,并分为 4 组:≤1cm、1.1 至 2cm、2.1 至 3cm 和>3cm。我们进行了逻辑回归和决策曲线分析。
总体而言,45 例(4.8%)患者肿瘤大小≤1cm,141 例(15.1%)肿瘤大小为 1.1 至 2cm,247 例(26.5%)肿瘤大小为 2.1 至 3cm,499 例(53.5%)肿瘤大小>3cm。在调整了标准临床病理特征影响的术前预测模型中,肿瘤直径>2cm(优势比,2.38;95%置信区间,1.70-3.32;P<0.001)和>3cm(优势比,1.81;95%置信区间,1.38-2.38;P<0.001)与≥pT2 病理分期独立相关。>2cm 直径截断值的加入使模型曲线下面积从 58.8%提高到 63.0%。决策曲线分析显示,临床净获益为 0.09,每 100 例患者减少 8 例。
2cm 截断值似乎最有助于识别有≥pT2 UTUC 风险的患者。这证实了欧洲泌尿外科协会(European Association of Urology)当前的风险分层指南。肿瘤大小本身不足以进行最佳风险分层,而是需要一系列特征来选择最适合保留肾脏手术的候选者。